Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide.
No risks detected for DPA from our risk checks.
Flawless balance sheet and undervalued.
Share Price & News
How has Daito PharmaceuticalLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DPA has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: DPA exceeded the German Pharmaceuticals industry which returned 6.1% over the past year.
Return vs Market: DPA exceeded the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is Daito PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Daito PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DPA (€24.8) is trading below our estimate of fair value (€58.26)
Significantly Below Fair Value: DPA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DPA is good value based on its PE Ratio (10x) compared to the Pharmaceuticals industry average (23.1x).
PE vs Market: DPA is good value based on its PE Ratio (10x) compared to the German market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: DPA is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: DPA is good value based on its PB Ratio (1.2x) compared to the DE Pharmaceuticals industry average (2.1x).
How is Daito PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DPA's forecast earnings growth (6.4% per year) is above the savings rate (-0.4%).
Earnings vs Market: DPA's earnings (6.4% per year) are forecast to grow slower than the German market (13.1% per year).
High Growth Earnings: DPA's earnings are forecast to grow, but not significantly.
Revenue vs Market: DPA's revenue (4.5% per year) is forecast to grow slower than the German market (5.1% per year).
High Growth Revenue: DPA's revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DPA's Return on Equity is forecast to be low in 3 years time (10.9%).
How has Daito PharmaceuticalLtd performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DPA has high quality earnings.
Growing Profit Margin: DPA's current net profit margins (8.7%) are higher than last year (7.9%).
Past Earnings Growth Analysis
Earnings Trend: DPA's earnings have grown by 10.8% per year over the past 5 years.
Accelerating Growth: DPA's earnings growth over the past year (22.9%) exceeds its 5-year average (10.8% per year).
Earnings vs Industry: DPA earnings growth over the past year (22.9%) exceeded the Pharmaceuticals industry -0.3%.
Return on Equity
High ROE: DPA's Return on Equity (11.3%) is considered low.
Return on Assets
Return on Capital Employed
How is Daito PharmaceuticalLtd's financial position?
Financial Position Analysis
Short Term Liabilities: DPA's short term assets (¥28.0B) exceed its short term liabilities (¥13.3B).
Long Term Liabilities: DPA's short term assets (¥28.0B) exceed its long term liabilities (¥3.0B).
Debt to Equity History and Analysis
Debt Level: DPA's debt to equity ratio (11.9%) is considered satisfactory.
Reducing Debt: DPA's debt to equity ratio has reduced from 44.6% to 11.9% over the past 5 years.
Debt Coverage: DPA's debt is well covered by operating cash flow (187.7%).
Interest Coverage: DPA earns more interest than it pays, so coverage of interest payments is not a concern.
Inventory Level: DPA has a high level of physical assets or inventory.
Debt Coverage by Assets: DPA's debt is covered by short term assets (assets are 7x debt).
What is Daito PharmaceuticalLtd's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Daito PharmaceuticalLtd before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: DPA's dividend (1.31%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.52%).
High Dividend: DPA's dividend (1.31%) is low compared to the top 25% of dividend payers in the German market (3.92%).
Stability and Growth of Payments
Stable Dividend: DPA's dividends per share have been stable in the past 10 years.
Growing Dividend: DPA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (6.5%), DPA's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yasunobu Otsuga (69yo)
Mr. Yasunobu Otsuga has been the President of Daito Pharmaceutical Co., Ltd. since August 2012 and serves as its Chief Executive Officer. Mr. Otsuga Joined Daito Pharmaceutical Co., Ltd. In March 1975. Mr. ...
|CEO, President & Representative Director||0yrs||no data||2.46% ¥8.0m|
|Senior MD & Director||7.5yrs||no data||0.12% ¥389.2k|
|VP & Director||18.4yrs||no data||no data|
|External Director||0yrs||no data||0.13% ¥416.7k|
|Director||0yrs||no data||0.27% ¥875.1k|
|External Director||0yrs||no data||no data|
Experienced Board: DPA's board of directors are seasoned and experienced ( 12.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Daito Pharmaceutical Co.,Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Daito Pharmaceutical Co.,Ltd.
- Ticker: DPA
- Exchange: DB
- Founded: 1942
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥39.243b
- Listing Market Cap: JP¥324.967m
- Shares outstanding: 12.82m
- Website: https://www.daitonet.co.jp
Number of Employees
- Daito Pharmaceutical Co.,Ltd.
- 326, Yokamachi
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4577||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Mar 2010|
|DPA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2010|
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was founded in 1942 and is headquartered in Toyama, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/27 21:58|
|End of Day Share Price||2020/02/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.